ERBB2 and breast carcinoma: To know whether or not the serum sCD14 could act as a biomarker for prediction of the LN+ER/PR-Her2+ status breast cancer recurrence, a 3-years follow-up study on the 90 LN+ER/PR-Her2+ status breast cancer patients was conducted.